BARCELONA, Jan. 29, 2026 — Ahead Therapeutics, a Spanish biotechnology company focused on transformative solutions for autoimmune diseases, today announced it has been awarded a prestigious Industry Discovery and Development Partnership (IDDP) grant from Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.
This strategic award will support Ahead Therapeutics in advancing its proprietary MiMi-ToP (Mimicking Tolerogenic Particles) platform, which is designed to promote the restoration of antigen-specific immune tolerance (ASIT) through an in vivo immune-reprogramming approach. MiMi-ToP is based on a well-established physiological mechanism involved in peripheral immune tolerance—the clearance of apoptotic cells—and biomimics this process using phosphatidylserine-based liposomes encapsulating disease-relevant autoantigen/s. In preclinical studies, this approach has shown the potential to restore long-term immune balance and reduce autoimmune activity across multiple disease models, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, myasthenia gravis, and others.
The IDDP grant will enable accelerated research and development activities in type 1 diabetes therapy, including the optimization and characterization of a multi-autoantigen formulation including multiple autoantigens relevant to type 1 diabetes, as well as the development of an industrially scalable lyophilization process. Together, these efforts will advance Ahead Therapeutics’ program in type 1 diabetes toward IND readiness.
“Restoring immune tolerance to insulin-producing beta cells offers the potential for providing sustained rebalancing of the immune system and effectively halting the progression of T1D,” said Dr. Joshua Vieth, Senior Director of Research at Breakthrough T1D. “We’re excited about the opportunity this approach represents for those impacted by type 1 diabetes, and we look forward to working with the team at Ahead Therapeutics and supporting the advancement of their novel MiMi-ToP platform.”
“Our team is deeply honored to receive this IDDP award from Breakthrough T1D,” said Marti Dalmases, CEO of Ahead Therapeutics. “This support validates the potential of our platform to make meaningful progress toward transformative therapies for people living with type 1 diabetes. With Breakthrough T1D’s partnership, we are positioned to advance our technology more rapidly and strategically than ever before.”
About the Ahead Therapeutics–Breakthrough T1D Collaboration
This partnership combines Ahead Therapeutics’ scientific and technological expertise with Breakthrough T1D’s mission-driven funding model and deep experience in accelerating translational research. Together, the organizations aim to de-risk critical development steps, accelerate progress toward IND readiness, and advance new therapeutic options for people living with type 1 diabetes.
About Ahead Therapeutics
Ahead Therapeutics is a biotech company dedicated to pioneering a breakthrough in vivo immune reprogramming platform that enable next-generation solutions autoimmune diseases. With a multidisciplinary team of scientists and engineers, Ahead Therapeutics is committed to advancing scientific breakthroughs and accelerating the translation of research into real-world impact for people living with T1D.
